3 Results for "

HCC-15

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "HCC-15" in MCE Product Catalog:

Cat. No.: HY-153065
CAS No.: 2914879-10-8
Purity:  98.39%
Research Areas:  

Cancer

KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity .
loading...
    loading...
Cat. No.: HY-153066
CAS No.: 2914878-00-3
Purity:  98.09%
Synonyms: KIF18A-IN-7
Research Areas:  

Cancer

VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research .
loading...
    loading...
Cat. No.: HY-169262
CAS No.: 1001957-60-3
Target:  

Phospholipase Apoptosis

Research Areas:  

Cancer

PLD-IN-1 (Compound 3r) is an orally active inhibitor for phospholipase D with an IC50 of 1.97 μM. PLD-IN-1 reduces the expression of CD24, CD47 and PD-L1, enhances the calreticulin expression, and thus modulates the immune evasion mechanism in lung cancer cells by promoting the phagocytosis of cancer cells by macrophages. PLD-IN-1 inhibits the cell viability of lung cancer cell A549, HCC44, H460 and HCC15 with IC50 of 18.44, 22.31, 24.85 and 21.45 μM, respectively. PLD-IN-1 can induce apoptosis and inhibits migration in cell A549. PLD-IN-1 enhances the level of pro-inflammatory M1 macrophages and decreases the level of anti-inflammatory M2 macrophages, exhibits antitumor efficacy in mouse model .
loading...
    loading...